225 related articles for article (PubMed ID: 32229503)
21. Histone tail analysis reveals H3K36me2 and H4K16ac as epigenetic signatures of diffuse intrinsic pontine glioma.
An S; Camarillo JM; Huang TY; Li D; Morris JA; Zoltek MA; Qi J; Behbahani M; Kambhampati M; Kelleher NL; Nazarian J; Thomas PM; Saratsis AM
J Exp Clin Cancer Res; 2020 Nov; 39(1):261. PubMed ID: 33239043
[TBL] [Abstract][Full Text] [Related]
22. Developing H3K27M mutant selective radiosensitization strategies in diffuse intrinsic pontine glioma.
Parsels LA; Wahl DR; Koschmann C; Morgan MA; Zhang Q
Neoplasia; 2023 Mar; 37():100881. PubMed ID: 36724689
[TBL] [Abstract][Full Text] [Related]
23. Signal Transduction in Diffuse Intrinsic Pontine Glioma.
Duchatel RJ; Jackson ER; Alvaro F; Nixon B; Hondermarck H; Dun MD
Proteomics; 2019 Nov; 19(21-22):e1800479. PubMed ID: 31328874
[TBL] [Abstract][Full Text] [Related]
24. Clinical, imaging, and molecular analysis of pediatric pontine tumors lacking characteristic imaging features of DIPG.
Chiang J; Diaz AK; Makepeace L; Li X; Han Y; Li Y; Klimo P; Boop FA; Baker SJ; Gajjar A; Merchant TE; Ellison DW; Broniscer A; Patay Z; Tinkle CL
Acta Neuropathol Commun; 2020 Apr; 8(1):57. PubMed ID: 32326973
[TBL] [Abstract][Full Text] [Related]
25. ALK2 inhibitors display beneficial effects in preclinical models of
Carvalho D; Taylor KR; Olaciregui NG; Molinari V; Clarke M; Mackay A; Ruddle R; Henley A; Valenti M; Hayes A; Brandon AH; Eccles SA; Raynaud F; Boudhar A; Monje M; Popov S; Moore AS; Mora J; Cruz O; Vinci M; Brennan PE; Bullock AN; Carcaboso AM; Jones C
Commun Biol; 2019; 2():156. PubMed ID: 31098401
[TBL] [Abstract][Full Text] [Related]
26. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.
Konstantinopoulos PA; Wilson AJ; Saskowski J; Wass E; Khabele D
Gynecol Oncol; 2014 Jun; 133(3):599-606. PubMed ID: 24631446
[TBL] [Abstract][Full Text] [Related]
27. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
[TBL] [Abstract][Full Text] [Related]
28. Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG.
Ehteda A; Simon S; Franshaw L; Giorgi FM; Liu J; Joshi S; Rouaen JRC; Pang CNI; Pandher R; Mayoh C; Tang Y; Khan A; Ung C; Tolhurst O; Kankean A; Hayden E; Lehmann R; Shen S; Gopalakrishnan A; Trebilcock P; Gurova K; Gudkov AV; Norris MD; Haber M; Vittorio O; Tsoli M; Ziegler DS
Cell Rep; 2021 Apr; 35(2):108994. PubMed ID: 33852836
[TBL] [Abstract][Full Text] [Related]
29. Combined treatment with CBP and BET inhibitors reverses inadvertent activation of detrimental super enhancer programs in DIPG cells.
Wiese M; Hamdan FH; Kubiak K; Diederichs C; Gielen GH; Nussbaumer G; Carcaboso AM; Hulleman E; Johnsen SA; Kramm CM
Cell Death Dis; 2020 Aug; 11(8):673. PubMed ID: 32826850
[TBL] [Abstract][Full Text] [Related]
30. Allosteric inhibition of PPM1D serine/threonine phosphatase via an altered conformational state.
Miller PG; Sathappa M; Moroco JA; Jiang W; Qian Y; Iqbal S; Guo Q; Giacomelli AO; Shaw S; Vernier C; Bajrami B; Yang X; Raffier C; Sperling AS; Gibson CJ; Kahn J; Jin C; Ranaghan M; Caliman A; Brousseau M; Fischer ES; Lintner R; Piccioni F; Campbell AJ; Root DE; Garvie CW; Ebert BL
Nat Commun; 2022 Jun; 13(1):3778. PubMed ID: 35773251
[TBL] [Abstract][Full Text] [Related]
31. Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma.
Wu CE; Esfandiari A; Ho YH; Wang N; Mahdi AK; Aptullahoglu E; Lovat P; Lunec J
Br J Cancer; 2018 Feb; 118(4):495-508. PubMed ID: 29235570
[TBL] [Abstract][Full Text] [Related]
32. Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes.
Castel D; Philippe C; Calmon R; Le Dret L; Truffaux N; Boddaert N; Pagès M; Taylor KR; Saulnier P; Lacroix L; Mackay A; Jones C; Sainte-Rose C; Blauwblomme T; Andreiuolo F; Puget S; Grill J; Varlet P; Debily MA
Acta Neuropathol; 2015 Dec; 130(6):815-27. PubMed ID: 26399631
[TBL] [Abstract][Full Text] [Related]
33. Chaetocin-mediated SUV39H1 inhibition targets stemness and oncogenic networks of diffuse midline gliomas and synergizes with ONC201.
Xin DE; Liao Y; Rao R; Ogurek S; Sengupta S; Xin M; Bayat AE; Seibel WL; Graham RT; Koschmann C; Lu QR
Neuro Oncol; 2024 Apr; 26(4):735-748. PubMed ID: 38011799
[TBL] [Abstract][Full Text] [Related]
34. Senescence Induced by BMI1 Inhibition Is a Therapeutic Vulnerability in H3K27M-Mutant DIPG.
Balakrishnan I; Danis E; Pierce A; Madhavan K; Wang D; Dahl N; Sanford B; Birks DK; Davidson N; Metselaar DS; Meel MH; Lemma R; Donson A; Vijmasi T; Katagi H; Sola I; Fosmire S; Alimova I; Steiner J; Gilani A; Hulleman E; Serkova NJ; Hashizume R; Hawkins C; Carcaboso AM; Gupta N; Monje M; Jabado N; Jones K; Foreman N; Green A; Vibhakar R; Venkataraman S
Cell Rep; 2020 Oct; 33(3):108286. PubMed ID: 33086074
[TBL] [Abstract][Full Text] [Related]
35. Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG.
Anastas JN; Zee BM; Kalin JH; Kim M; Guo R; Alexandrescu S; Blanco MA; Giera S; Gillespie SM; Das J; Wu M; Nocco S; Bonal DM; Nguyen QD; Suva ML; Bernstein BE; Alani R; Golub TR; Cole PA; Filbin MG; Shi Y
Cancer Cell; 2019 Nov; 36(5):528-544.e10. PubMed ID: 31631026
[TBL] [Abstract][Full Text] [Related]
36. Fimepinostat Impairs NF-κB and PI3K/AKT Signaling and Enhances Gemcitabine Efficacy in H3.3K27M-Diffuse Intrinsic Pontine Glioma.
Wang D; Yan K; Yu H; Li H; Zhou W; Hong Y; Guo S; Wang Y; Xu C; Pan C; Tang Y; Liu N; Wu W; Zhang L; Xi Q
Cancer Res; 2024 Feb; 84(4):598-615. PubMed ID: 38095539
[TBL] [Abstract][Full Text] [Related]
37. A kinome-wide shRNA screen uncovers vaccinia-related kinase 3 (VRK3) as an essential gene for diffuse intrinsic pontine glioma survival.
Silva-Evangelista C; Barret E; Ménez V; Merlevede J; Kergrohen T; Saccasyn A; Oberlin E; Puget S; Beccaria K; Grill J; Castel D; Debily MA
Oncogene; 2019 Sep; 38(38):6479-6490. PubMed ID: 31324890
[TBL] [Abstract][Full Text] [Related]
38. Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma.
Nagaraja S; Vitanza NA; Woo PJ; Taylor KR; Liu F; Zhang L; Li M; Meng W; Ponnuswami A; Sun W; Ma J; Hulleman E; Swigut T; Wysocka J; Tang Y; Monje M
Cancer Cell; 2017 May; 31(5):635-652.e6. PubMed ID: 28434841
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of Rad51 sensitizes breast cancer cells with wild-type PTEN to olaparib.
Zhao Q; Guan J; Zhang Z; Lv J; Wang Y; Liu L; Zhou Q; Mao W
Biomed Pharmacother; 2017 Oct; 94():165-168. PubMed ID: 28759753
[TBL] [Abstract][Full Text] [Related]
40. Targeting DNA Repair and Survival Signaling in Diffuse Intrinsic Pontine Gliomas to Prevent Tumor Recurrence.
Sharma M; Barravecchia I; Teis R; Cruz J; Mumby R; Ziemke EK; Espinoza CE; Krishnamoorthy V; Magnuson B; Ljungman M; Koschmann C; Chandra J; Whitehead CE; Sebolt-Leopold JS; Galban S
Mol Cancer Ther; 2024 Jan; 23(1):24-34. PubMed ID: 37723046
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
